scholarly journals VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer

2021 ◽  
Author(s):  
Yingxia Ning ◽  
Zhaoyang Zeng ◽  
Yuao Deng ◽  
Weifeng Feng ◽  
Lun Huang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Cisplatin Chemoresistance

scholarly journals Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2061
Author(s):  
Cecilia Pozzi ◽  
Matteo Santucci ◽  
Gaetano Marverti ◽  
Domenico D’Arca ◽  
Lorenzo Tagliazucchi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Thymidylate Synthase ◽  
Ovarian Cancer Cell ◽  
Ovarian Cancer Cells ◽  
Preclinical Research ◽  
Cancer Cell Growth ◽  
X Ray ◽  
Synergistic Inhibition

Combining drugs represent an approach to efficiently prevent and overcome drug resistance and to reduce toxicity; yet it is a highly challenging task, particularly if combinations of inhibitors of the same enzyme target are considered. To show that crystallographic and inhibition kinetic information can provide indicators of cancer cell growth inhibition by combinations of two anti-human thymidylate synthase (hTS) drugs, we obtained the X-ray crystal structure of the hTS:raltitrexed:5-fluorodeoxyuridine monophosphate (FdUMP) complex. Its analysis showed a ternary complex with both molecules strongly bound inside the enzyme catalytic cavity. The synergistic inhibition of hTS and its mechanistic rationale were consistent with the structural analysis. When administered in combination to A2780 and A2780/CP ovarian cancer cells, the two drugs inhibited ovarian cancer cell growth additively/synergistically. Together, these results support the idea that X-ray crystallography can provide structural indicators for designing combinations of hTS (or any other target)-directed drugs to accelerate preclinical research for therapeutic application.

scholarly journals Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy

2007 ◽  
Vol 6 (5) ◽  
pp. 795-801 ◽  
Author(s):  
Dineo Khabele ◽  
Deok-Soo Son ◽  
Angelika K. Parl ◽  
Gary L. Goldberg ◽  
Leonard H. Augenlicht ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Gene Silencing ◽  
Cancer Cell ◽  
Histone Deacetylases ◽  
Ovarian Cancer Cell ◽  
Class I ◽  
Cancer Cell Growth ◽  
Drug Induced ◽  
Or Gene

scholarly journals Cell growth inhibitory effects of polyphenols with naphthalene skeleton against cisplatin-resistant ovarian cancer cells

2018 ◽  
Vol 61 (6) ◽  
pp. 697-701 ◽  
Author(s):  
Soon Young Shin ◽  
Youngshim Lee ◽  
Jihyun Park ◽  
Doseok Hwang ◽  
Geunhyeong Jo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Inhibitory Effects ◽  
Growth Inhibitory

scholarly journals FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor

2007 ◽  
Vol 267 (1-2) ◽  
pp. 26-37 ◽  
Author(s):  
Y. Li ◽  
S. Ganta ◽  
C. Cheng ◽  
R. Craig ◽  
R.R. Ganta ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Growth Factor ◽  
Cell Growth ◽  
Cancer Cell ◽  
Ovarian Cancer Cell ◽  
Cancer Cell Growth

Abstract PO-132: Upregulated LYL1 promotes epithelial ovarian cancer (EOC) cell growth and metastasis

2022 ◽  
Author(s):  
Damieanus Ochola ◽  
Shirisha Jonnalagadda ◽  
Swetha Peddibhotla ◽  
Tasmin Omy ◽  
Mark Reedy ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Epithelial Ovarian Cancer

Using 3D perfusion bioreactor system to studying cell biology of ovarian cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e17558-e17558
Author(s):  
Alba Martínez ◽  
Molly Buckley ◽  
Joel Berry ◽  
Rebecca Christian Arend
Keyword(s):  
Ovarian Cancer ◽  
Cell Culture ◽  
Cell Growth ◽  
Cell Lines ◽  
Culture Media ◽  
Tumor Biology ◽  
Perfusion Bioreactor ◽  
Suitable Model ◽  
Cell Culture Media ◽  
Bioreactor System

e17558 Background: Epithelial Ovarian Cancer (EOC) is the most common cause of death among gynecological malignancies. This is a result of the high rate of recurrence and chemo-resistance in EOC patients. Therefore, the development of new therapeutics is crucial. A major factor contributing to this is the lack of therapeutic candidates is lack of translational accuracy in preclinical models. Recently, 3-dimensional (3-D) models have aided in accurately recreating tumor biology. We have developed an EOC 3-D perfused bioreactor system that recapitulates EOC tumor biology and incorporates tumor biomechanical regulation. This model allows for us to more accurately predict the clinical response of new drug candidates, which aids in elimination of ineffective candidates prior to clinical trials. Methods: EOC cell lines (luciferase-taggedSKOV-3 and OVCAR-8) were embedded in a relevant extracellular matrix (ECM) and injected into a perfused, polydimethylsiloxane (PDMS) bioreactor. Microchannels were embedded in matrigel so that the cell culture media with or without chemotherapy could flow through the perfused PDMS to provide nutrient delivery and gas exchange enhancing viability and function of surrounding cells. The bioreactors were connected to a peristaltic pump that allowed for the cell culture media to perfuse over a 7-day period. We monitored cell viability using bioluminescence imaging (BLI), immunohistochemistry (IHC), and lactate dehydrogenase (LDH) release in media. Results: BLI showed a linear increase in SKOV-3 and OVCAR-8 cell growth over 7 days. These results were confirmed by IHC measuring the number of nucleated cells per micron2. Graphical representation of the region of interest (ROI) showed a high correlation between IHC staining of nucleated cells and BLI score. IHC analysis of PAX8 staining was positive and proved that the perfusion bioreactor system maintains EOC biology over time. In addition, our results suggest that the bioreactor is a suitable model for drug preclinical testing in both cell lines as well as in patients’ samples. Conclusions: Our preliminary results using the 3D EOC perfused, PDMS bioreactor model showed increased EOC cell growth overtime, while maintaining original EOC histology. Moreover, our results suggest that this model could provide a novel platform to study therapeutic interventions in EOC. Our ultimate goal is to implement ovarian cancer microenvironment components (e.g. immune cells) into bioreactor system to study different drug treatments to better determine drug candidate’s translational efficacy.

scholarly journals The hallmarks of ovarian cancer: proliferation and cell growth

2020 ◽  
Vol 15 ◽  
pp. 27-37
Author(s):  
Raquel López-Reig ◽  
José Antonio López-Guerrero
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Cancer Proliferation

scholarly journals BRDT promotes ovarian cancer cell growth

2020 ◽  
Vol 11 (11) ◽  
Author(s):  
Ling Chen ◽  
Shang Cai ◽  
Jing-mei Wang ◽  
Ying-ying Huai ◽  
Pei-Hua Lu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Ovarian Cancer Cell ◽  
Scid Mice ◽  
Ovarian Cancer Cells ◽  
Cancer Cell Growth ◽  
Primary Ovarian Cancer ◽  
And Migration ◽  
Proliferation And Migration

AbstractBromodomain testis-specific factor (BRDT) is a member of the bromodomain and extra-terminal (BET) family proteins. Its expression and potential functions in ovarian cancer were examined. We show that BRDT is overexpressed in human ovarian cancer tissues and in established (CaOV3)/primary ovarian cancer cells. However, its expression is low in ovarian epithelial tissues and cells. Significantly, shRNA-induced silencing or CRISPR/Cas9-mediated knockout of BRDT inhibited ovarian cancer cell growth, viability, proliferation and migration, and induced significant apoptosis activation. Conversely, exogenous overexpression of BRDT, by a lentiviral construct, augmented CaOV3 cell proliferation and migration. In CaOV3 cells expression of two key BRDT target genes, polo-like kinase 1 (PLK1) and aurora kinase C (AURKC), was downregulated by BRDT shRNA or knockout, but upregulated with BRDT overexpression. In vivo, xenograft tumors-derived from BRDT-knockout CaOV3 cells grew significantly slower than control tumors in severe combined immunodeficient (SCID) mice. Furthermore, intratumoral injection of BRDT shRNA lentivirus potently inhibited the growth of primary ovarian cancer xenografts in SCID mice. Downregulation of PLK1 and AURKC was detected in BRDT-knockout and BRDT-silenced tumor tissues. Collectively, BRDT overexpression promotes ovarian cancer cell progression. Targeting BRDT could be a novel strategy to treat ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document